Cargando…

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study

Objective To determine the relative risks of prostate cancer incidence, metastasis, and mortality associated with screening by serum prostate specific antigen (PSA) levels at age 60. Design Population based cohort study. Setting General male population of Sweden taking part in a screening trial in G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsson, Sigrid, Assel, Melissa, Sjoberg, Daniel, Ulmert, David, Hugosson, Jonas, Lilja, Hans, Vickers, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968958/ https://www.ncbi.nlm.nih.gov/pubmed/24682399 http://dx.doi.org/10.1136/bmj.g2296

Ejemplares similares

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2010)

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project
por: Assel, Melissa J., et al.
Publicado: (2017)

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate
por: Kohestani, Kimia, et al.
Publicado: (2021)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2013)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
por: Klein, Robert J., et al.
Publicado: (2022)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
por: Vickers, Andrew J, et al.
Publicado: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
por: Ulmert, David, et al.
Publicado: (2008)

Spotlight on prostate cancer: the latest evidence and current controversies
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
por: Mühlberger, Nikolai, et al.
Publicado: (2017)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Effects of surgeon variability on oncologic and functional outcomes in a population-based setting
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Prostate cancer screening—when to start and how to screen?
por: Kohestani, Kimia, et al.
Publicado: (2018)

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial
por: Frånlund, Maria, et al.
Publicado: (2022)

Estimating patient health in prostate cancer treatment counseling
por: Chesnut, Gregory T., et al.
Publicado: (2023)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
por: Ma, Chaoran, et al.
Publicado: (2023)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

Active surveillance for prostate cancer
por: Shill, Daniela K., et al.
Publicado: (2021)

Who and when should we screen for prostate cancer? Interviews with key opinion leaders
por: Carlsson, Sigrid, et al.
Publicado: (2015)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
por: Benchikh, Amine, et al.
Publicado: (2010)

Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
por: Wallström, Jonas, et al.
Publicado: (2021)

The Brier score does not evaluate the clinical utility of diagnostic tests or prediction models
por: Assel, Melissa, et al.
Publicado: (2017)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
por: Callender, Tom, et al.
Publicado: (2019)

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
por: Bryant, Richard J., et al.
Publicado: (2015)

Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study
por: Stattin, Pär, et al.
Publicado: (2010)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
por: Getaneh, Abraham M., et al.
Publicado: (2020)

Benefits and harms of mammography screening
por: Løberg, Magnus, et al.
Publicado: (2015)

Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
por: Lodeta, Branimir, et al.
Publicado: (2023)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy
por: Haese, Alexander, et al.
Publicado: (2020)

Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer
por: Axén, Elin, et al.
Publicado: (2021)

Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial
por: Nyberg, Martin, et al.
Publicado: (2020)

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
por: Wu, Xiaoning, et al.
Publicado: (2019)

Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
por: Nordström, Tobias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ficq7dfdkoaeqbre071kkq3ks3